Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Get Free Report) major shareholder Millennium Management Llc acquired 9,533 shares of the firm’s stock in a transaction dated Monday, March 30th. The stock was bought at an average price of $25.86 per share, with a total value of $246,523.38. Following the purchase, the insider directly owned 145,678 shares in the company, valued at approximately $3,767,233.08. This trade represents a 7.00% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Millennium Management Llc also recently made the following trade(s):
- On Thursday, March 26th, Millennium Management Llc sold 1,857 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $28.12, for a total value of $52,218.84.
- On Friday, March 27th, Millennium Management Llc sold 505 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.81, for a total value of $13,539.05.
- On Monday, March 30th, Millennium Management Llc sold 888 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $26.61, for a total value of $23,629.68.
- On Friday, March 27th, Millennium Management Llc acquired 15,321 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $26.61 per share, with a total value of $407,691.81.
- On Thursday, March 26th, Millennium Management Llc acquired 5,731 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $28.62 per share, with a total value of $164,021.22.
- On Tuesday, March 31st, Millennium Management Llc sold 1,591 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $25.49, for a total value of $40,554.59.
- On Wednesday, April 1st, Millennium Management Llc sold 1,150 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $31.65, for a total value of $36,397.50.
- On Wednesday, April 1st, Millennium Management Llc acquired 6,175 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $34.49 per share, with a total value of $212,975.75.
- On Tuesday, March 31st, Millennium Management Llc acquired 6,005 shares of Sensei Biotherapeutics stock. The stock was bought at an average price of $28.16 per share, with a total value of $169,100.80.
- On Thursday, April 2nd, Millennium Management Llc sold 7,666 shares of Sensei Biotherapeutics stock. The shares were sold at an average price of $32.12, for a total value of $246,231.92.
Sensei Biotherapeutics Stock Performance
Shares of SNSE opened at $20.43 on Friday. The stock has a 50-day simple moving average of $28.89 and a 200-day simple moving average of $17.87. The stock has a market capitalization of $27.38 million, a PE ratio of -1.23 and a beta of -0.18. Sensei Biotherapeutics, Inc. has a 1 year low of $5.25 and a 1 year high of $36.76.
Analyst Upgrades and Downgrades
Several research firms recently weighed in on SNSE. Leerink Partners began coverage on Sensei Biotherapeutics in a research note on Monday, April 20th. They set an “outperform” rating and a $50.00 target price for the company. Wall Street Zen cut Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research note on Friday, April 24th. Finally, Zacks Research upgraded Sensei Biotherapeutics to a “hold” rating in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $40.00.
View Our Latest Stock Report on Sensei Biotherapeutics
Institutional Investors Weigh In On Sensei Biotherapeutics
An institutional investor recently raised its position in Sensei Biotherapeutics stock. Renaissance Technologies LLC increased its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE – Free Report) by 10.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,516 shares of the company’s stock after purchasing an additional 1,100 shares during the quarter. Renaissance Technologies LLC owned approximately 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent quarter. Institutional investors own 10.50% of the company’s stock.
Trending Headlines about Sensei Biotherapeutics
Here are the key news stories impacting Sensei Biotherapeutics this week:
- Positive Sentiment: Sensei Biotherapeutics reported first-quarter 2026 results and said the quarter was “transformational,” highlighting the acquisition of Faeth Therapeutics and a concurrent $200 million private placement backed by leading life sciences investors, which may strengthen the balance sheet and support the company’s strategy. Sensei Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Neutral Sentiment: The company also disclosed that major shareholder Millennium Management made several purchases in late March and early April, which can signal insider confidence, although the filing also showed some offsetting sales in the same period. SEC insider filing
- Negative Sentiment: The earnings release showed a very large quarterly loss, with reported EPS of ($131.45) versus expectations of ($0.62), underscoring continued financial volatility and likely limiting enthusiasm for the stock. Quarterly earnings press release
Sensei Biotherapeutics Company Profile
Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.
The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.
Featured Stories
- Five stocks we like better than Sensei Biotherapeutics
- MarketBeat Week in Review – 05/11 – 05/15
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
